Dashboard
Manage Tickers

AUPHAurinia Pharmaceuticals Inc.

Nasdaq auriniapharma.com


$ 5.09 $ -0.07 (-1.35 %)    

Friday, 03-May-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 5.1
$ 5.39
$ 0.00 x 0
$ 0.00 x 0
$ 5.09 - $ 5.52
$ 4.71 - $ 12.43
1,695,317
na
729.4M
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-15-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-24-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

aurinia-reiterates-2024-net-product-revenue-guidance-of-200m-220m
Aurinia Reiterates 2024 Net Product Revenu...
05/02/2024 10:03:59

aurinia-pharmaceuticals-q1-2024-gaap-eps-007-beats-014-estimate-sales-50300m-beat-47453m-estimate
Aurinia Pharmaceuticals Q1 2024 GAAP EPS $...
05/02/2024 10:01:03

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate ...

aurinia-pharmaceuticals-announced-several-initiatives-to-improve-understanding-of-the-seriousness-of-lupus-nephritis-and-the-need-for-frequent-screening-and-appropriate-management
Aurinia Pharmaceuticals Announced Several ...
05/01/2024 10:19:10

fda-approves-updated-lupkynis-voclosporin-label-to-include-long-term-data-from-the-aurora-clinical-program
FDA Approves Updated LUPKYNIS (voclosporin...
04/30/2024 10:13:19

The updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established beyo...

hc-wainwright--co-reiterates-buy-on-aurinia-pharmaceuticals-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Auri...
03/01/2024 19:09:24

HC Wainwright & Co. analyst Ed Arce reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and maintains $13 price ...

aurinia-receives-exemptive-relief-from-canadian-securities-regulators-for-share-repurchase-program
Aurinia Receives Exemptive Relief from Can...
02/29/2024 14:10:15

cantor-fitzgerald-maintains-overweight-on-aurinia-pharmaceuticals-lowers-price-target-to-10
Cantor Fitzgerald Maintains Overweight on ...
02/23/2024 17:11:00

Cantor Fitzgerald analyst Olivia Brayer maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight and lowers the pri...

analog-devices-to-rally-around-19-here-are-10-top-analyst-forecasts-for-thursday
Analog Devices To Rally Around 19%? Here A...
02/22/2024 12:23:19

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

hc-wainwright--co-maintains-buy-on-aurinia-pharmaceuticals-lowers-price-target-to-13
HC Wainwright & Co. Maintains Buy on Aurin...
02/22/2024 11:44:19

HC Wainwright & Co. analyst Ed Arce maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and lowers the price targ...

rbc-capital-maintains-outperform-on-aurinia-pharmaceuticals-lowers-price-target-to-8
RBC Capital Maintains Outperform on Aurini...
02/16/2024 16:13:39

RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Outperform and lowers the price tar...

why-herbalife-shares-are-trading-lower-by-around-36-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Herbalife Shares Are Trading Lower By ...
02/15/2024 18:20:19

Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings.

aurinia-pharmaceuticals-finds-no-buyer-after-strategic-business-review-launches-stock-buyback
Aurinia Pharmaceuticals Finds No Buyer Aft...
02/15/2024 14:51:00

Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review con...

aurinia-pharmaceuticals-initiates-share-repurchase-program-of-up-to-150m
Aurinia Pharmaceuticals Initiates Share Re...
02/15/2024 11:09:11

aurinia-pharmaceuticals-reaffirms-2024-revenue-guidance-of-200m-220m-vs-21787m-est
Aurinia Pharmaceuticals Reaffirms 2024 Rev...
02/15/2024 11:04:15

aurinia-pharmaceuticals-q4-2023-gaap-eps-019-misses-016-estimate-sales-4510m-beat-4433m-estimate
Aurinia Pharmaceuticals Q4 2023 GAAP EPS $...
02/15/2024 11:00:56

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimat...

earnings-scheduled-for-february-15-2024
Earnings Scheduled For February 15, 2024
02/15/2024 10:17:01

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

reuters-reported-aurinia-finds-no-buyer-to-announce-150m--share-buyback
Reuters Reported Aurinia Finds No Buyer, T...
02/15/2024 10:11:53

earnings-outlook-for-aurinia-pharmaceuticals
Earnings Outlook For Aurinia Pharmaceuticals
02/14/2024 20:01:53

whats-going-on-with-aurinia-pharmaceuticals-stock
What's Going On With Aurinia Pharmaceutica...
01/05/2024 15:56:23

Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, ...

aurinia-pharmaceuticals-reports-preliminary-unaudited-total-net-revenue-for-q4-of-45m-vs-estimate-of-442m-and-and-full-year-2023-preliminary-revenue-of-176m-vs-17471m estimate
Aurinia Pharmaceuticals Reports Preliminar...
01/05/2024 11:26:46

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION